Royal Marsden Hospital

Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update

Retrieved on: 
Friday, April 5, 2024
TME, Development, FAP, Doctor of Philosophy, Patient, Doxorubicin, Tumor microenvironment, Royal Marsden Hospital, MD, AACR, Research and development, Institute of Cancer Research, Poster, Heterotrimeric G protein, BST, AIM, Fine chemical

Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.

Key Points: 
  • Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.
  • A copy of the abstract will be available on Avacta’s website at: https://avacta.com/about/scientific-resources/ .
  • Christina Coughlin will provide a video presentation overview examining the data presented in the poster.
  • Alastair Smith, Avacta Chief Executive Officer, will also be hosting a webinar on Wednesday, April 10 2024 at 5.30pm BST to discuss the data.

Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024

Retrieved on: 
Tuesday, March 5, 2024
Institute of Cancer Research, FAP, Royal Marsden Hospital, Doctor of Philosophy, Heterotrimeric G protein, MD, TME, AACR, AIM, Tumor microenvironment, Patient, Poster, Fine chemical

Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024

Key Points: 
  • Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024
    Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces updated clinical data from the First-in-Human Phase 1 trial of the peptide drug conjugate, AVA6000 will be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April 2024.
  • The results will be presented in the Phase 1 Clinical Trials 2 Poster Session on April 9, 2024 as detailed below.
  • Title: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
    First Author: Udai Banerji, MD, PhD, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust
    For further information from Avacta Group plc, please contact:

RaySearch Laboratories: Year-end report 2023

Retrieved on: 
Friday, February 23, 2024
Mass, Royal Marsden Hospital, Medical college, RaySearch Laboratories, Paul Scherrer Institute, Interim, Artemis, CBCT, Policy

RaySearch secured an order from Israel-based P-Cure and expanded collaboration focusing on advanced proton therapy solutions.

Key Points: 
  • RaySearch secured an order from Israel-based P-Cure and expanded collaboration focusing on advanced proton therapy solutions.
  • The Royal Marsden in the UK will be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch.
  • Telephone: +46 (0)8 510 530 00, [email protected]
    Telephone: +46 (0)8 510 530 00, [email protected]
    The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act.
  • CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch's year-end report for January-December 2023 at a webcast to be held in English on Friday, February 23, 2024 at 10:00-10:30 a.m. CET.

The Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch

Retrieved on: 
Thursday, February 8, 2024
RaySearch Laboratories, Research, Patient, Radiation, Institute of Cancer Research, Physics, Disease, Royal Marsden Hospital, Anatomy, Hospital

Thanks to funding from The Royal Marsden Cancer Charity, the center recently acquired two additional Radixact treatment delivery machines from Accuray with the intention to utilize these machines for OART.

Key Points: 
  • Thanks to funding from The Royal Marsden Cancer Charity, the center recently acquired two additional Radixact treatment delivery machines from Accuray with the intention to utilize these machines for OART.
  • ARTemis is a collaborative effort between RaySearch and Accuray, aiming to provide an online adaptive solution for clinicians using the RayStation treatment planning system with the Radixact Treatment Delivery System.
  • The Royal Marsden in Sutton plans to implement the full ARTemis package, which has also been funded by The Royal Marsden Cancer Charity.
  • Johan Löf, founder and CEO, RaySearch, says: "I am a strong believer of the clinical benefits of adaptive radiation therapy.

SOPHiA GENETICS Highlights Near-Term Growth Strategy at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 10, 2024
Constant, Patient, PST, Forecasting, Research, Dasa, Liquid biopsy, Westin St. Francis, HRD, Cancer, GENETICS, Royal Marsden Hospital, Genomics, Conference, Platform, Webcast, J. P. Morgan, Sophia Genetics, FY, Q3, Growth

BOSTON and ROLLE, Switzerland, Jan. 10, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, will share an overview of its near-term growth strategy, fueled by strong adoption and opportunity for the SOPHiA DDM™ Platform, in a presentation at the 42nd annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 9:00 a.m. PST.

Key Points: 
  • New customer count for 2023 includes 87 core genomics customers globally2, resulting in a current network of 750+ customers using SOPHiA DDM™ globally3.
  • New U.S.-based customer Tennessee Oncology exploring MSK-ACCESS® powered with SOPHiA DDM™, as well as Latin American healthcare network Dasa expanding to incorporate the liquid biopsy application.
  • I could not be more excited about the opportunities that lie ahead and SOPHiA GENETICS' ability to capitalize," said Jurgi Camblong, PhD., Chief Executive Officer and Co-founder of SOPHiA GENETICS.
  • The SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution continues to be a strong driver of growth just two years after launch.

CV6 Therapeutics Receives MHRA Approval for Novel Cancer Therapy Phase 1a Clinical Trial

Retrieved on: 
Thursday, December 14, 2023
CV6, Immune system, Drug development, Lung, Cancer, Inflammation, Melanoma, DNA, Mouth, Apyrase, Therapy, MHRA, Royal Marsden Hospital, Thymidylate synthase, Gastrointestinal cancer, University, ECMC, Toxicity, Patient, Safety

Cancer cell DNA uracilation by CV6-168 is aided by combination with standard cancer therapies including thymidylate synthase (TS) inhibitors such as 5-fluorouracil (5-FU).

Key Points: 
  • Cancer cell DNA uracilation by CV6-168 is aided by combination with standard cancer therapies including thymidylate synthase (TS) inhibitors such as 5-fluorouracil (5-FU).
  • The UK multi-centre Phase 1a clinical trial will combine CV6-168 with infusional 5-FU to treat gastrointestinal cancer patients, such as colon, gastric, and pancreatic cancers as well as other tumor types such as melanoma, lung, and ovarian cancers.
  • The trial is expected to have dosed its first patient in Q1 2024, with trial read-outs expected in H1 2025.
  • CV6 CEO and Founder Dr Robert Ladner said, “This regulatory approval is a key milestone as we progress CV6-168 into a first-in-human Phase 1a clinical trial.

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NDA, Paclitaxel, Woman, Institute of Cancer Research, Research, Safety, Food, Avutometinib, Cancer, Letrozole, Disease, Verastem Oncology, Patient, Anastrozole, GOG, PFS, Consultant, RAMP, Breakthrough therapy, Part, FDA, NHS foundation trust, FRAME, ORR, The Institute, Ovarian cancer, FRCP, Doctor of Philosophy, Physician, Accelerated approval (FDA), Royal Marsden Hospital, Pharmaceutical industry, MBBS, Topotecan

“Patients and treating physicians have advocated for more research and development in support of LGSOC.

Key Points: 
  • “Patients and treating physicians have advocated for more research and development in support of LGSOC.
  • At Verastem Oncology, we are moving with urgency to offer a Phase 3 study specifically directed at this disease in an effort to address this need,” said Dan Paterson, President and Chief Executive Officer, Verastem Oncology.
  • RAMP 301 is a global trial with enrollment open in the U.S. and planned enrollment in Canada, the United Kingdom, Europe, Australia, and Korea.
  • Dr. Grisham and Dr. Banerjee are paid consultants for Verastem Oncology.

Automata Technologies: Joe Stringer appointed Executive Chairman & Director of Corporate Development (EMEA)

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Technology, Manufacturing, Health, Pharmaceutical, Robotics, Research, Engineering, Science, Machinery, Electronic Design Automation, The Royal Marsden NHS Foundation Trust, Francis Crick Institute, Octopus Group, Investment, Drug development, Ernst, NHS, Growth, Google Health, Ernst & Young, Royal Marsden Hospital, Corporate development, Holland & Barrett, Patient, Automation, Management, Pharmaceutical industry, Automaton

Automata Technologies (‘Automata’ or the ‘Company’), a leading automation company powering life sciences labs, has appointed Joe Stringer Executive Chairman and Director of Corporate Development for the UK and EMEA.

Key Points: 
  • Automata Technologies (‘Automata’ or the ‘Company’), a leading automation company powering life sciences labs, has appointed Joe Stringer Executive Chairman and Director of Corporate Development for the UK and EMEA.
  • Joe joins Automata from Octopus Ventures where he was most recently Head of Healthtech Investments.
  • Through his role at Octopus Ventures, Joe has been involved with Automata since January 2022 as an investor and Investor Director, and remains on the Board of Directors.
  • Mostafa Elsayed, Founder and CEO of Automata, commented:
    "It is great to welcome Joe to the Automata family full-time.

Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023

Retrieved on: 
Monday, October 23, 2023
Patient, FDA, Research, Open-label trial, MRI, ESMO, Phase 2 (graffiti artist), OTCQX, DT, Congress, Plantar fibromatosis, Phase 3, Poster, OLE, Clinical trial, The Institute, Part, Safety, Chief Medical Officer (Ireland), European Society for Medical Oncology, Royal Marsden Hospital, GSI, Consultant, BIW, Pharmaceutical industry, Sarcoma

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that new data from the RINGSIDE study evaluating its lead investigational candidate AL102 for the treatment of desmoid tumors (DT) are being presented today at the European Society for Molecular Oncology (ESMO) Congress 2023, taking place October 20th to 24th in Madrid, Spain. The data are from Phase 2 (Part A) of the study and from the Open Label Extension (OLE). The results are featured in a poster being presented by Professor Robin Jones, Team Leader in Sarcoma Clinical Trials at The Institute of Cancer Research and Consultant Medical Oncologist at The Royal Marsden, UK.

Key Points: 
  • The data are from Phase 2 (Part A) of the study and from the Open Label Extension (OLE).
  • The results are featured in a poster being presented by Professor Robin Jones, Team Leader in Sarcoma Clinical Trials at The Institute of Cancer Research and Consultant Medical Oncologist at The Royal Marsden, UK.
  • “The RINGSIDE results continue to improve over time, with more patients in this latest Phase 2 and OLE data cut demonstrating responses to treatment with AL102,” said Kenneth Berlin, President and CEO of Ayala.
  • The safety results appear consistent with the GSI class.”
    The ongoing Phase 2/3 RINGSIDE clinical trial is a randomized, global multi-center study evaluating AL102 in patients with progressing desmoid tumors.

PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

Retrieved on: 
Monday, October 23, 2023
MA, Neoplasm, Society for Immunotherapy of Cancer, ESMO, Infection, Vaccine, CD4, HPV, MD, Cytokine, Doctor of Philosophy, Cervical cancer, TH1, HNSCC, CD8, Biotechnology, Immunotherapy, Radiation, Chemokine, Oncology, Blood, Safety, European Society for Medical Oncology, Royal Marsden Hospital, Patient, PDSB, Cancer

The data presented during the European Society for Medical Oncology Congress 2023 (ESMO Congress 2023) provided preliminary insight to the pre-existing immune responses in advanced HPV-positive HNSCC patients and potential changes to the immune profile after treatment.

Key Points: 
  • The data presented during the European Society for Medical Oncology Congress 2023 (ESMO Congress 2023) provided preliminary insight to the pre-existing immune responses in advanced HPV-positive HNSCC patients and potential changes to the immune profile after treatment.
  • “Generation of multifunctional, anti-tumor T cells with the relevant cytokine and chemokine profiles are necessary for effective long-term control of tumor growth and clinical outcomes.
  • This initial study focused on understanding the immunological profile of advanced head and cancer patients in the blood,” said Kevin Harrington, PhD, Professor of Biological Cancer Therapies, The Royal Marsden.
  • “This preliminary study suggests that PDS0101 may promote a TH1 predominant cytokine profile as well as induction of important T cell activating chemokines.